News

Wednesday January 31, 2024

Clinical development update

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Clinical development update Positive Results from XF-73 Dermal Safety Study XF-73 Dermal to be progressed towards clinical evaluation for the treatment of […]

Monday January 22, 2024

Appointment of Nominated Adviser and Sole Broker

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Appointment of Nominated Adviser and Sole Broker Brighton, United Kingdom ‐ 22 January 2024 ‐ Destiny Pharma (AIM: DEST), a clinical stage […]

Thursday January 4, 2024

Year End Business Update

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Year End Business Update Brighton, United Kingdom – 4 January 2024 – Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the […]

Tuesday October 17, 2023

XF Pipeline Update Meeting

Destiny Pharma plc (“Destiny Pharma” or “the Company”) XF Pipeline Update Meeting with Leading Experts and New Microbiological Data on XF-73 Brighton, United Kingdom – 17 October 2023 – Destiny […]

Tuesday October 17, 2023

Publication of new microbiological data for XF-73

Destiny Pharma plc (“Destiny Pharma” or “the Company”) New publication shows XF‐73 drug potent against 2,527 Staphylococcus isolates Largest study of its kind to date demonstrates effectiveness of XF‐73 against […]

Wednesday September 27, 2023

Notice of XF Pipeline Update Meeting

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Notice of XF Pipeline Update Meeting Brighton, United Kingdom – 27 September 2023 – Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused […]

Wednesday September 20, 2023

Interim results for the six months ended 30 June 2023

Destiny Pharma plc (“Destiny Pharma” or the “Company”) Interim results for the six months ended 30 June 2023 Active discussions with potential partners for XF-73 nasal supported by new market […]

Monday July 31, 2023

Publication of new data for XF-73

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Publication of new data demonstrates significantly superior efficacy of XF-73 compared to a leading topical antibiotic against MRSA in skin infection models […]

Wednesday July 19, 2023

Board changes including appointment of new CEO

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Board changes including appointment of new CEO Brighton, United Kingdom – 19 July 2023: Destiny Pharma plc (AIM: DEST), a clinical stage […]

Thursday July 6, 2023

Positive findings from recent SAB meeting

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive findings from recent Scientific Advisory Board meeting Confirms proposed Phase 3 development pathway and identifies new life cycle management targets for […]